Latest Venous ulcer Stories
Results Show a Rate of 80% to 100% Wound Closure Within Just Four Weeks in the Vast Majority of Patients Treated REHOVOT, Israel, March 19, 2015 /PRNewswire/ -- CollPlant Ltd.
ST. LOUIS, March 10, 2015 /PR Newswire/ -- VENITI, Inc., a St.
Yehiel Tal: "The trial is a major milestone towards commercialization of the Company's products in global markets" REHOVOT, Israel, December 1, 2014 /PRNewswire/ --
VLU STUDY PATIENTS TREATED WITH EPIFIX® ALLOGRAFT HAD DOUBLE THE RATE OF WOUND CLOSURE COMPARED TO CONTROL GROUP MARIETTA, Ga., Sept. 17, 2014 /PRNewswire/ -- MiMedx Group, Inc.
Access to Apligraf® is Improved for Veterans with Chronic Diabetic Foot Ulcers and Venous Leg Ulcers CANTON, Mass., Aug 4, 2014 /PRNewswire/ -- Organogenesis Inc.
REHOVOT, Israel, June 16, 2014 /PRNewswire/ -- CollPlant (TASE: CLPT), developer and manufacturer of human collagen-based medical products announces that it has received
Experienced biomaterials professional to lead company in development of new treatments for difficult to heal, chronic wounds using proprietary silk technology. Waltham,
EpiFix® is shown to promote rapid healing and return to function for patients and provide a potential for significant cost savings. MARIETTA, Ga., April 23, 2014 /PRNewswire/ -- EpiFix®,
CANTON, Mass. and ORLANDO, Fla., April 22, 2014 /PRNewswire/ -- This week, Organogenesis Inc.
ADDISON, Texas, April 7, 2014 /PRNewswire/ --ULURU Inc. (OTCQB: ULUR), is pleased to provide an update on the pharmacoeconomic analysis being conducted in Europe on Altrazeal(®), the